lower guid read-
cro
preannounc neg due
pre-announce neg market close
compani previous guid hit revenu coronaviru
crisi china expect see report start take toll
clinic trial oper march global spread viru result
increment neg impact note exit global research
site temporarili inaccess compani expect revenu
midpoint vs prior guid adj ebitda
adj ep detail
thought rest read-across cro
base impact march forecast organ revenu
ta flat ds csm compani see
headwind last least end despit note
book remain strong thu still expect strong recoveri end
similar expect coverag univers iclr
lh covanc see increment neg hit clinic trial oper continu
impact said magnitud impact depend variou
factor includ geograph exposur backlog mix therapeut area stage
studi start-up enrol vs enrol databas lock etc remot monitor
capabl among other last factor think iclr buy po
rel well-posit recent acquisit symphoni clinic provid
at-hom patient site support servic link believ alternate-sit
services/hybrid trial solut key capabl eventu enabl futur vision
virtual trial bring clinic patient reiter buy
demand drug devt servic remain robust despit near-term oper challeng
lower est po
lower adj ep est lower
po base recess concern in-
line iqv histor averag forward price-to-earnings multipl adj ep estimate
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
ia lead global provid
advanc analyt technolog solut
contract research servic life scienc
industri compani form
merger im health quintil world
seek improv clinic drug develop
commerci healthcar outcom
applic data scienc
posit due compani
differenti grow technolog analyt
solut healthi cro industri fundament
proven track record capit deploy
support growth think deliv mid-
augment double-digit adj ep
growth upcom year
segment detail impact
segment bulk impact ds
revenu increment hit revenu contract research
organ cro busi exit global research site
temporarili inaccess due travel/mobl restrict divers
healthcar resourc technolog analyt solut ta
revenu also increment hit revenu rel lower
magnitud due high portion recur licens revenu
segment lastli contract sale medic solut csm revenu perform
in-lin go forward busi may impact physician focu
attent crisi sale rep visit declin
reaffirm strong liquid
also re-affirmed maintain strong liquid posit cash
cash equival avail borrow capac
revolv credit facil iqv nearest signific matur term loan
moreov signific ebitda cushion rel
requir threshold two mainten coven credit facil interest
coverag ratio vs senior secur net leverag
vs assess line recent liquid
analysi see liquid analysi life scienc tool diagnost anim
earn call
due host earn confer call dial-in
price object base ep estim in-lin iclr
averag one-year price-to-earnings multipl last three year believ multipl
warrant given compani strong biopharma strateg partnership solid
execut track record higher qualiti earn mostli risk custom
concentr biopharma custom consolid soft drug spend downturn
biotech financ competit technolog risk execut risk regulatori risk
price object base adj ep estim in-lin
averag two-year forward price-to-earnings multipl last five year believ
multipl warrant evolv portfolio recent technolog win rate
cro book help improv growth next year risk soft drug
commerci spend downturn biotech financ technolog data supply/secur
regulatori risk competit execut risk biopharma custom consolid
juan avendano herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
